Astellas Pharma Inc.
Astellas Pharma Inc. Fundamental Analysis
Astellas Pharma Inc. (ALPMY) shows strong financial fundamentals with a PE ratio of 13.58, profit margin of 15.67%, and ROE of 20.39%. The company generates $2080.3B in annual revenue with strong year-over-year growth of 19.25%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 87.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze ALPMY's fundamental strength across five key dimensions:
Efficiency Score
WeakALPMY struggles to generate sufficient returns from assets.
Valuation Score
ExcellentALPMY trades at attractive valuation levels.
Growth Score
ModerateALPMY shows steady but slowing expansion.
Financial Health Score
ExcellentALPMY maintains a strong and stable balance sheet.
Profitability Score
ExcellentALPMY achieves industry-leading margins.
Key Financial Metrics
Is ALPMY Expensive or Cheap?
P/E Ratio
ALPMY trades at 13.58 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ALPMY's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Astellas Pharma Inc. at 2.51 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 6.60 times EBITDA. This is generally considered low.
How Well Does ALPMY Make Money?
Net Profit Margin
For every $100 in sales, Astellas Pharma Inc. keeps $15.67 as profit after all expenses.
Operating Margin
Core operations generate 18.97 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.39 in profit for every $100 of shareholder equity.
ROA
Astellas Pharma Inc. generates $9.04 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Astellas Pharma Inc. produces operating cash flow of $468.12B, showing steady but balanced cash generation.
Free Cash Flow
Astellas Pharma Inc. generates strong free cash flow of $416.47B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $232.48 in free cash annually.
FCF Yield
ALPMY converts 9.42% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.58
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.001
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.51
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.13
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.41
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.09
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.17
vs 25 benchmark
How ALPMY Stacks Against Its Sector Peers
| Metric | ALPMY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.58 | 29.28 | Better (Cheaper) |
| ROE | 20.39% | 820.00% | Weak |
| Net Margin | 15.67% | -19731.00% (disorted) | Strong |
| Debt/Equity | 0.41 | 0.26 | Weak (High Leverage) |
| Current Ratio | 1.09 | 4.69 | Neutral |
| ROA | 9.04% | -17993.00% (disorted) | Weak |
ALPMY outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Astellas Pharma Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
54.07%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-72.78%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-4.82%
Industry Style: Defensive, Growth, Innovation
Declining